According to the company, the Bioguard will offer surgeons, wound care clinicians, infection control experts and primary care doctors a new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA).
Bioguard is said to be the company’s latest new product entrant into the wound care market. Sales of the dressings are expected to commence in June, 2009.
Ed Quilty, CEO of Derma Sciences, said: “This clearance represents a significant milestone for Derma Sciences and provides another large step in implementing our strategic plan.
“We believe that Bioguard, a gauze-based dressing that has been shown to kill 99.999% of MRSA, will be a great asset to healthcare providers as they look for more effective and efficient ways to combat the transmission of virulent pathogens throughout their facilities.”